WEB ANNOUNCEMENT

BARDA and JPEO-CBRND help Humanigen evaluate drug to potentially prevent or treat cytokine storm caused by COVID-19

About Image

BARDA will provide technical assistance on a Phase 3 clinical trial underway to evaluate the use of a drug, lenzilumab, being developed by Humanigen, Inc., to prevent or treat an immune hyper-response called a cytokine storm.

Through a Cooperative Research and Development Agreement (CRADA) with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), BARDA will provide Humanigen subject matter expertise for statistical analysis, and manufacturing and regulatory activities to support drug development in advance of a potential Emergency Use Authorization (EUA) for COVID-19. Cytokine storm is a severe immune reaction in which the body releases a high level of cytokines in the blood in a short time frame, which can result in lung injury, and is associated with COVID-19 infections. Cytokine storm can also be triggered by the acute respiratory distress syndrome in severe cases of COVID-19. Lenzilumab is being evaluated as a treatment for cytokine storm, which may help prevent lung damage.

Lenzilumab is Humanigen's proprietary Humaneered® monoclonal antibody directed against granulocyte macrophage-colony stimulating factor (GM-CSF). GM-CSF is a cytokine secreted by immune cells, and high levels of it correlate with disease severity, cytokine storm, and respiratory failure in COVID-19 patients. A Phase 3 registration trial is ongoing at 18 approved clinical trial sites in the U.S. In addition, lenzilumab was selected by the National Institutes of Health (NIH) for its ACTIV-5 “Big Effect Trial.”

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership to develop a coordinated research strategy for prioritizing and speeding development of some of the most promising treatments and vaccines to treat or prevent SARS-COV-2 infections.

About Humanigen:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products. 

Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, they are trying to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation.

Last Updated: November 06, 2020

COVID-19 Medical Countermeasure Portfolio

This award is one component of BARDA's rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA's COVID-19 Portfolio to learn more.

Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov